---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical presentation - signs and symptoms. Topics: Motor symptoms: chorea; Motor symptoms: dystonia, bradykinesia, rigidity, and oculomotor disturbance; Motor symptoms: gait disturbance and falls; Cognitive symptoms: executive dysfunction and progressive decline; 6 further topics. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Motor symptoms: chorea

> “Chorea, an involuntary movement disorder consisting of nonrepetitive, nonperiodic jerking of limbs, face, or trunk, is the major sign of HD. Chorea is present in most individuals and typically increases in severity during the first ten years.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.6-2"></a>

### Motor symptoms: dystonia, bradykinesia, rigidity, and oculomotor disturbance

> “With advancing disease duration, chorea may decrease and other movement abnormalities such as bradykinesia, rigidity, and dystonia occur. Impairment in voluntary motor function is an early sign.”
> “Difficulty in initiating ocular saccades, slow and hypometric saccades, and problems in gaze fixation occur in up to 75% of symptomatic individuals”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “Early in the disease, they are primarily hyperkinetic with involuntary chorea. In later stages, however, hypokinesia with bradykinesia and dystonia may predominate.”

Source: [Ajitkumar et al. (2025)](https://www.ncbi.nlm.nih.gov/books/NBK559166/)

<a id="topic-2.2.1.6-3"></a>

### Motor symptoms: gait disturbance and falls

> “Compared to controls, Huntington patients had a decreased gait velocity (1.15 m/s versus 1.45 m/s, P < 0.001) and a decreased stride length (1.29 m versus 1.52 m, P < 0.001).”

Source: [Grimbergen et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18381643/)

<a id="topic-2.2.1.6-4"></a>

### Cognitive symptoms: executive dysfunction and progressive decline

> “A global and progressive decline in cognitive capabilities occurs in all individuals with HD. Cognitive changes include forgetfulness, slowness of thought processes, impaired visuospatial abilities, and impaired ability to manipulate acquired knowledge”
> “These initial changes often involve loss of mental flexibility and impairment of executive functions such as mental planning and organization of sequential activities.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “Chorea and other aspects of the movement disorder are the most visible aspect of the disease. However, non-motor features have greatest affect on functional independence and quality of life, so require recognition and management.”

Source: [Snowden (2017)](https://pubmed.ncbi.nlm.nih.gov/28961886/)

<a id="topic-2.2.1.6-5"></a>

### Psychiatric symptoms: depression, irritability, apathy, and anxiety

> “Ninety eight per cent of the patients exhibited neuropsychiatric symptoms, the most prevalent being dysphoria, agitation, irritability, apathy, and anxiety.”

Source: [Paulsen et al. (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1737562/)

> “Depression is the most common psychiatric manifestation, affecting 40% of individuals with HD, followed by anxiety”
> “Apathy is a common and disabling symptom that is related to disease stage and worsens with progression”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “Apathy was already present in 32% of preHD-A increasing to 62% of early-HD patients.”

Source: [Martinez-Horta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26898966/)

<a id="topic-2.2.1.6-6"></a>

### Psychiatric symptoms: suicidality

> “Eleven (20%) pre-motor and 20 (20%) motor symptomatic mutation carriers were considered suicidal compared to none of the non-carriers.”

Source: [Hubers et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22119091/)

<a id="topic-2.2.1.6-7"></a>

### Other symptoms: weight loss

> “Individuals with HD tend to experience substantial weight loss, reduced muscle mass, and lower body mass index compared to unaffected individuals.”
> “Individuals usually have very high calorie requirements to simply maintain their weight.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.6-8"></a>

### Other symptoms: dysarthria and dysphagia

> “Speech impairment reflects a combination of dysarthria and word-finding difficulties, and in advanced disease some individuals may progress to complete anarthria. Swallowing difficulties arise from incoordination of oral and pharyngeal muscles, and can lead to choking episodes and aspiration pneumonia, a frequent cause of death in HD.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.6-9"></a>

### Other symptoms: sleep and circadian disturbance

> “The most common sleep problems reported by HD patients include insomnia, difficulties in falling asleep, frequent nocturnal awakenings, and excessive daytime sleepiness.”

Source: [Herzog-Krzywoszanska and Krzywoszanski (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6474183/)

<a id="topic-2.2.1.6-10"></a>

### Juvenile Huntington's disease: presentation

> “In the first decade of life, individuals with juvenile HD present with common clinical manifestations of behavior disturbance and impairment of school performance, followed by dysarthria, seizures, rigidity, gait disturbances, bradykinesia, and dystonia”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “Seizures occur in 30 percent to 50 percent of children with this condition.”

Source: [MedlinePlus (2020)](https://medlineplus.gov/genetics/condition/huntington-disease/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
